TaperMeds — Deprescribing Software

Zoloft Tapering Guide

sertraline

SSRIFDA 1991
Try TaperMeds

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.

Overview

Sertraline is an SSRI antidepressant approved for major depressive disorder, OCD, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder. It is one of the most widely prescribed antidepressants worldwide.

Common Doses

25mg, 50mg, 100mg, 200mg

Formulations

Tablets: 25mg, 50mg, 100mg; Oral concentrate: 20mg/mL

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Potent and selective inhibitor of serotonin reuptake at the presynaptic membrane (SERT), with minimal effects on norepinephrine and dopamine reuptake. Also has mild affinity for the dopamine transporter.

Taper Notes

Hyperbolic taper recommended (~10% per step). Oral concentrate (20 mg/mL) supports precise sub-tablet dosing. GI symptoms predominate over neurological symptoms relative to other SSRIs.

Maudsley Deprescribing Guidance

Apply proportional reductions of ~10% of the prior dose every 2–4 weeks. Oral concentrate (20 mg/mL) is useful for increments below 25 mg, where tablet splitting becomes imprecise.

Tapering Protocol

Evidence-based phased reduction schedule. Always taper under medical supervision.

PhaseDurationNotes
Initial reductions~4 weeksReduce by ~25% of current dose using available tablet strengths. Higher SERT occupancy permits larger absolute steps.
Middle reductions4-6 weeksTransition to smaller tablet strengths or proportional 10–15% reductions. Monitor for GI disturbance, the most common early withdrawal sign.
Lower dose reductions6-8 weeksSwitch to oral concentrate (20 mg/mL) for fine titration; tablet splitting introduces unacceptable variability below 25 mg.
Final reductions6-10 weeksBelow 12.5 mg, use liquid dosing with proportional reductions and extend hold periods to 4+ weeks if symptoms emerge.

Withdrawal Timeline

Onset

1-2 days after dose reduction

📈Peak Severity

3-7 days

📉Resolution

2-3 weeks for acute symptoms

⚠️Protracted Risk

GI symptoms and irritability may linger 4-8 weeks. Brain zaps typically resolve within 1 month.

Clinical Pearls

Practical considerations for clinicians supervising Zoloft tapers.

  • 1Sertraline oral concentrate (20 mg/mL) is the preferred tool for fine titration below 25 mg; tablet splitting yields unreliable doses.
  • 2GI symptoms (nausea, loose stools, cramping) are commonly the earliest discontinuation sign in sertraline; symptomatic management with antiemetics or dietary adjustment is reasonable.
  • 3The terminal portion of the taper is disproportionately demanding; counsel the patient to expect this and slow the cadence rather than abandon the plan.
  • 4Sertraline has mild dopaminergic activity at higher doses; clinical experience suggests transient motivational decline during taper that resolves post-stabilization.
  • 5Encourage daily symptom tracking. Sertraline discontinuation often presents subtly and cumulatively — objective data improves taper-pacing decisions.

Common Withdrawal Symptoms

brain zapsdizzinessirritabilityinsomniaGI upset

Interactions & Safety

Drug Interactions

  • MAOIs — contraindicated (serotonin syndrome risk)
  • Pimozide — contraindicated
  • Disulfiram — oral concentrate contains alcohol

Food Interactions

  • Food increases peak plasma levels by ~25%
  • Oral concentrate must be diluted before use; avoid mixing with grapefruit juice
  • Avoid alcohol during treatment

Contraindications

  • MAOIs within 14 days
  • Pimozide
  • Disulfiram (oral concentrate contains alcohol)

Toxicity

Serotonin syndrome in overdose or with serotonergic combinations. QT prolongation reported rarely. GI bleeding risk increased with NSAIDs.

Pharmacokinetics

ADME Profile

Absorption

Slowly absorbed after oral administration, Tmax 4.5–8.4 hours. Bioavailability subject to extensive first-pass metabolism. Food increases Tmax slightly.

Distribution

~20 L/kg

Metabolism

Extensive hepatic metabolism primarily via CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 to N-desmethylsertraline (substantially less active).

Elimination

Renal (~40–45% as metabolites) and fecal (~40–45%). Less than 0.2% excreted unchanged in urine.

Protein Binding

~98%

Clearance

~1.5 L/min (oral clearance)

Build Zoloft taper plans in minutes

TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.

Try TaperMeds

Other Medication Profiles

Book a Free Demo